Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer

Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as... We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-1+ and Flt-1- patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-1- and Flt-1+ patients were 45 and 67.6 months, respectively (p=0.014). The mean recurrence-free survival periods for Flk-1+ and Flk-1- patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bulletin of Experimental Biology and Medicine Springer Journals

Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/expression-of-flt-1-and-flk-1-receptors-for-vascular-endothelial-5khmeOPPko

References (13)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Plenum Publishing Corporation
Subject
Biomedicine; Biomedicine, general; Internal Medicine; Cell Biology; Pathology; Laboratory Medicine
ISSN
0007-4888
eISSN
1573-8221
DOI
10.1023/A:1024975627843
Publisher site
See Article on Publisher Site

Abstract

We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-1+ and Flt-1- patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-1- and Flt-1+ patients were 45 and 67.6 months, respectively (p=0.014). The mean recurrence-free survival periods for Flk-1+ and Flk-1- patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival.

Journal

Bulletin of Experimental Biology and Medicine – Springer Journals

Published: Oct 5, 2004

There are no references for this article.